Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/198662
Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Lleixa and Caballero-avila et al. report that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis. Multiple sclerosis is a tissue-specific autoimmune disease of the central nervous system in which the antigen(s) remains elusive. Antibodies targeting the flotillin-1/2 complex have been described in 1-2% of the patients in a recent study. Other candidate antigens as anoctamin-2 or neurofascin-155 have been previously described in multiple sclerosis patients, although their clinical relevance remains uncertain. Our study aims to analyse the frequency and clinical relevance of antibodies against neurofascin-155, anoctamin-2 and flotillin-1/2 complex in multiple sclerosis. Serum (n = 252) and CSF (n = 50) samples from 282 multiple sclerosis patients were included in the study. The control group was composed of 260 serum samples (71 healthy donors and 189 with other neuroinflammatory disorders). Anti-flotillin-1/2, anti-anoctamin-2 and anti-neurofascin-155 antibodies were tested by cell-based assays using transfected cells. We identified six multiple sclerosis patients with antibodies against the flotillin-1/2 complex (2.1%) and one multiple sclerosis patient with antibodies against anoctamin-2 (0.35%). All multiple sclerosis patients were negative for anti-neurofascin-155 antibodies. Three of the anti-flotillin-1/2 positive patients showed anti-flotillin-1/2 positivity in other serum samples extracted at different moments of their disease. Immunoglobulin G subclasses of anti-flotillin-1/2 antibodies were predominantly one and three. We confirm that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis.
Matèries
Matèries (anglès)
Citació
Citació
LLEIXÀ, Cinta, CABALLERO ÁVILA, Marta, PASCUAL GOÑI, Elba, MARTÍN AGUILAR, Lorena, VIDAL, Nuria, TEJADA, Clara, VALDÉS HEVIA, Eduardo, ZÁRATE, Elisa, VESPERINAS, Ana, COLLET, Roger, FRANCO LEYVA, Teresa, MARTÍNEZ MARTÍNEZ, Laura, MOGA, Esther, CORTÉS VICENTE, Elena, ROJAS GARCÍA, Ricard, GÓMEZ ANSON, Beatriz, GIL, Anna, GONZÁLEZ MINGOT, Cristina, BRIEVA, Luis, MARTÍNEZ YÉLAMOS, Sergio, QUEROL, Luis. Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis. _Brain Communications_. 2023. Vol. 5, núm. 2. [consulta: 8 de abril de 2026]. ISSN: 2632-1297. [Disponible a: https://hdl.handle.net/2445/198662]